Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG FLEXPEN versus NOVOLOG INNOLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG FLEXPEN versus NOVOLOG INNOLET.
NOVOLOG FLEXPEN vs NOVOLOG INNOLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog that lowers blood glucose by binding to insulin receptors, facilitating cellular uptake of glucose, and inhibiting hepatic glucose production.
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase activity, which leads to glucose transporter translocation and metabolic effects.
Subcutaneous injection; 0.5 to 1.0 unit/kg/day divided into doses at mealtimes; dose individualization based on metabolic needs and blood glucose monitoring.
Subcutaneous injection, 0.5-1.0 unit/kg/day in divided doses, with meals.
None Documented
None Documented
Terminal elimination half-life: 5-7 minutes (free insulin aspart in plasma); clinically, the prolonged action (up to 6 hours) reflects continued absorption from subcutaneous depot, not elimination half-life
Terminal half-life: 81 minutes (range 70–90 minutes) for subcutaneous administration; reflects absorption-rate limited elimination
Primarily renal (60-80% as unchanged drug via glomerular filtration and tubular reabsorption); biliary/fecal excretion minimal (<2%)
Renal: approximately 30% of total clearance as unchanged drug; hepatobiliary/fecal: minor (less than 1%)
Category C
Category C
Insulin Analog
Insulin Analog